A Japanese study evaluated the effect of CYP3A4-5 and ATP-binding cassette transporter (ABCC2) polymorphisms on lenvatinib pharmacokinetics in patients with thyroid cancer. This evidence concerns the gene ABCA4 and thyroid cancer.